

# Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3 **Co-immobilized poly(ethylene glycol)-*block*-polyamines promote sensitivity and**  
4 **restrict biofouling on gold sensor surface for detecting**  
5 **Factor IX in human plasma**  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 Thangavel Lakshmipriya<sup>1</sup>, Yukichi Horiguchi<sup>1</sup>, and Yukio Nagasaki<sup>1,2,3\*</sup>  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 <sup>1</sup>Department of Material Sciences, Graduate School of Pure and Applied Sciences

29 <sup>2</sup>Master's School of Medicinal Sciences, Graduate School of Comprehensive Human  
30 Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8573

31 <sup>3</sup>International Center for Materials for Nanoarchitectonics Satellite (WPI-MANA) National  
32 Institute of Material Science (NIMS) and University of Tsukuba, 1-1-1 Tennoudai,  
33 Tsukuba, Ibaraki 305-8573, Japan  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 **\*Corresponding author:**  
49

50 Prof. Yukio Nagasaki

51 E-mail address: yukio@nagalabo.jp  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In order to detect an extremely low amount of human coagulation factor IX (FIX), polyethylene glycol (PEG)/aptamer co-immobilized surface was constructed using original PEG-polyamine surface modification agents on surface plasmon resonance (SPR) sensor chip. Initially, a gold (Au) sensor chip of SPR was modified using poly(ethylene glycol)-*b*-poly[2-(N,N-dimethylamino)ethyl methacrylate] (PEG-*b*-PAMA) followed by treatment with SH-dT<sub>20</sub> and was duplexed with anti-FIX aptamer extended using A<sub>24</sub>. Further, the co-immobilization of pentaethylenehexamine-terminated poly(ethylene glycol) (N6-PEG) on the sensing surface completely quenched the bio-fouling. On this dual tethered PEG-surface, we determined that the dissociation constant for FIX-aptamer interaction was 37±10 pM, and the sensitivity of detection could reach upto 800 fM on using aptamer-FIX-antibody sandwich pattern detected by gold nanoparticle-conjugated anti-mouse antibody. We could detect FIX in the presence of abundant albumin. Further, to mimic the actual detection of FIX in clinical samples, we demonstrated our experimental evidence with human blood plasma instead of FIX. Higher-sensitivity was attained due to dual polymers immobilized on Au surface, and this can emerge as a common strategy for any aptamer-protein interactions. Selective binding of the aptamer in human blood plasma shown here indicates the suitability of the present strategy for detection in clinically relevant samples.

Key words: Factor IX, Surface Plasmon Resonance, PEG-*b*-PAMA, N6-PEG, gold nanoparticle, aptamer

## Introduction

Biomolecular recognition is considered as an important feature to understand the events of a disease and gene regulations. The first biosensor with signal recognition elements and transducers was reported in 1962, which is considered as the basis for sensor development.<sup>1</sup> After this initial report, various sensors have been proposed and developed using versatile signal detection methods.<sup>2</sup> Among different sensing systems, which include surface plasmon resonance (SPR) and other sensors mimics, SPR dominates as a major in label-free or labeled method of detection.<sup>3</sup> However, a method of detection without chemical tags is highly essential for scalable biosensor technology with real-time monitoring and high sensitivity. Even though, the sensitivity varies with different systems, sensitivity is the prime determining factor for the quality of successful sensors.<sup>4</sup> Different surface functionalization chemistries with suitable probes have been proposed to improve the sensing system. From the very early stage of sensor development, antibodies have been used as probes, and in 1967, the first immobilized antibody-solid surface was proposed by Catt and Niall.<sup>5</sup> Later, an advanced method

1  
2  
3 such as ELISA was introduced<sup>6</sup>, followed by several antibody-sensing strategies on  
4 solid surfaces were established.<sup>7</sup> Even though antibodies have been potential  
5 molecules for sensor development since the past several decades, in 1990, an alternate  
6 molecule to substitute the antibodies was developed, which was called 'aptamer' or  
7 'chemical antibody.' A strategy called Systemic Evolution of Ligands by Exponential  
8 Enrichment (SELEX) was introduced by three independent researchers to generate the  
9 aptamers, and to find the selective molecules from the randomized molecules.<sup>8-10</sup>  
10 Aptamers have the potential characteristics and behave similar to antibodies. A  
11 combination of antibody- and aptamer-sensing strategy have been proposed, because  
12 these molecules could complement each other.<sup>11</sup>  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Aptamers or antibodies immobilized on solid surfaces have a lower antigen  
24 capturing efficiency compared to in-solution based detections due to random  
25 orientations and steric hindrances by interaction with the solid surface.<sup>12-14</sup> To fabricate  
26 an efficient solid-surface sensor, proper immobilization of probe or receptor molecule on  
27 the surface of sensor is a crucial step, and correctly oriented higher-density  
28 immobilization would lead to an improved level of detection.<sup>14</sup> Right orientation of  
29 biomolecules on the solid surface was accomplished by co-immobilization of inert  
30 materials such as polymers.<sup>15</sup> Poly(ethylene glycol) (PEG) is one of the popular  
31 polymers, which is chemically inert, provides terminal hydroxyl groups that can be used  
32 as anchors for functional groups, is nontoxic, and dispersible in water due to hydrogen  
33 bonding between water molecules and ether oxygen molecules of the PEG chain.  
34 Surface modification with PEG (so-called 'PEGylation') is shown to have non-fouling  
35 effects due to the hydrophilic and flexible nature of this polymer.<sup>16-19</sup> PEG-block  
36 polymers (PEG-*b*-polymers) attracted the attention of the researchers in the past,  
37 especially in the fields of biotechnology, pharmaceuticals, and medicine for the  
38 purposes of bio-recognition, cosmetics, drug delivery systems, and microsystems.<sup>20,21</sup>  
39 PEG-*b*-polymer-modified surfaces are highly efficient in reducing protein adsorption  
40 from a mixture of samples, such as blood, thereby improving biocompatibility.<sup>22,23</sup>  
41 Natural polymers such as BSA and casein may not help in these aspects as they  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 contain immunoglobulin (IgG) that may interfere with antigen binding and cross-react  
4 with secondary antibodies.<sup>24</sup> PEG-based polymers are also considered as an efficient  
5 component in the development of biointerfaces and for applications as non-ionic  
6 surfactants, lubricants, and adhesives.<sup>15,25</sup> The length and density of the constructed  
7 polymers play a role in the improvement of sensitivity and specificity of a given sensor.  
8 However, increased chain-length tend to be less dense due to steric exclusion of PEG-  
9 chains on the immobilized surface.<sup>26,27</sup> Instead, a mixture of long and short PEG-chains  
10 overcome the density issues, due to the occupying properties of short chains between  
11 the interface of two long chains and were found to reduce non-specific adsorption onto  
12 the sensing surface.<sup>19,28-32</sup>

21  
22  
23 On the other hand, among different reported solid-sensing surfaces, gold (Au) is  
24 one of the preferred metals for sensing due to easy water dispersal, compatibility with  
25 surface functionalization, biological non-reactivity, and ability to be tailored with uniform  
26 and different nano-sizes.<sup>33-37</sup> In this report, a combination of Au surface and PEG-  
27 polymers were used to develop the higher sensing system with the assistance of a  
28 SPR-based Biacore system. The excitation of surface plasmon by monochromatic  
29 waves on the metal-coated surface surrounded by biological fluid environment and the  
30 excitation of surface plasmon by light is known as a SPR. Absorption of molecules on  
31 the receptor layer of biosensor changes the refractive index of the layer, thereby  
32 reporting the event of binding (Supplementary Figure S1a-c). With the SPR-based  
33 sensors, PEG-assisted surface has been shown to have higher-sensitivity.<sup>38-40</sup> A  
34 specially synthesized PEG-polymers, such as poly(ethylene glycol)-b-poly[2-(N,N-  
35 dimethylamino)ethyl methacrylate] (PEG-*b*-PAMA) and pentaethylenehexamine-  
36 terminated poly(ethylene glycol) (N6-PEG), were demonstrated for different sensing  
37 surface with higher non-fouling and increased sensitivity.<sup>41-43</sup> One of the most important  
38 factors in improving the effectiveness of the sensor is the correct orientation of  
39 immobilized biomolecules on the given sensing surface.<sup>15</sup> The above PEG-*b*-polymers  
40 (PEG-*b*-PAMA and N6-PEG) have an unique participation in making properly oriented  
41 bio-molecular immobilization with higher numbers.<sup>11,41,42</sup> In the present study, the  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 strategy with sandwich pattern of aptamer-Factor IX (FIX)-antibody was used to  
4 demonstrate the applications of with the above described PEG-*b*-polymers, PEG-*b*-  
5 PAMA and N6-PEG.  
6  
7  
8  
9

10 The biological importance of FIX is reflected in Hemophilia B (Christmas  
11 disease), where the FIX concentration in the plasma reaches abnormal levels from the  
12 normal level of around 5  $\mu\text{g/mL}$  (87 nM). The human plasma has clotting factors other  
13 than FIX, as well as major additional components such as albumin (45 mg/mL). It is  
14 therefore important to conform that FIX can be detected amidst such high levels of  
15 albumin. If we can detect FIX selectively among a mixture of components, it is  
16 anticipated that we will be able to precisely determine the active level of FIX. In this  
17 study, we demonstrated the detection of FIX using the following sensing strategy: (i)  
18 initially Au sensor chip of SPR was modified with PEG-*b*-PAMA followed by SH-dT<sub>20</sub>; (ii)  
19 aptamer-A<sub>24</sub> was complemented with SH-dT<sub>20</sub>; (iii) unreacted Au surface was blocked  
20 by N6-PEG; (iv) FIX was allowed to interact with aptamer; (v) anti-FIX mouse IgG was  
21 incubated on the FIX-modified surface; or (vi) anti-mouse IgG antibody-conjugated gold  
22 nanoparticle (GNP) was allowed to interact with anti-FIX antibody; and (vii) all the  
23 interactions were monitored by SPR.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 37 **Experimental**

### 38 **Reagents and biomolecules**

39 All oligoes were commercially synthesized by Tsukuba Oligo company. TaKaRa Ex Taq,  
40 DuraScribe® T7 Transcription Kit, propionic acid, factor IX, Monoclonal Anti-FIX  
41 antibody produced in mouse, human serum, and bovine serum albumin (BSA) were  
42 purchased from sigma Aldrich, USA. Anti-Mouse IgG (H+L)-40 nm GNP conjugate was  
43 from Cytodiagnosics, Canada. Sensor chip was from GE healthcare, Japan. N6-PEG  
44 (Block master) was kindly provided by JSR (Tokyo, Japan). Synthesis of PEG-*b*-PAMA  
45 is outlined by Miyamoto et al.<sup>37</sup> and Horiguchi et al.<sup>43</sup> All the reagents were stored  
46 according to the suppliers' recommendations.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Enzymatic synthesis of aptamer

A stable 33-mer (2'-fluoro-modified) RNA-aptamer, which was previously reported by Rusconi et al.,<sup>44</sup> was followed and its ability to bind to FIX or FIXa was verified.<sup>44,45</sup> The aptamer was synthesized on a synthetic DNA template by enzymatic reaction (in vitro transcription) using T7 RNA polymerase. The T7 promoter region (letters are highlighted in italics) was maintained at the 5'-end of the aptamer to generate the RNA molecules. The following DNA template, 5'-*AGTAATACGACTCACTATAGGG*GATGGGGACTATAACCGCGTAATGCTG-3' was used to prepare the double-stranded DNA. A polymerase chain reaction (PCR) was performed using the above DNA template and amplified using appropriate primers (5'-*AGTAATACGACTCACTATAGG*-3' [forward] and 5'-(T)<sub>24</sub>ATGGGGAGGCAGCATTACGCGGTATA-3' [reverse]) and the TaKaRa Ex Taq mix. Twenty PCR cycles were completed at 94°C for 70 s, 55°C for 50 s, and 72°C for 70 s. After proper PCR amplification, the PCR product was precipitated in ethanol and used for RNA preparation by *in vitro* T7 transcription. Transcription was performed at 37°C overnight, using a DuraScribe transcription kit (Epicentre Biotechnologies, USA), and the reaction was terminated by adding an equal volume of 2x urea buffer (7 M urea, 50 mM EDTA [ethylenediaminetetraacetic acid], 90 mM tris-borate containing 0.05% bromophenol blue). Afterwards, the reaction mixture was heated at 90°C for 2 min and loaded onto a 12% polyacrylamide gel containing 7 M urea for fractionation. The RNA band was visualized using UV light, and the band was extracted from the excised gel-piece. The RNAs were precipitated in ethanol and dried under vacuum, re-dissolved in ddH<sub>2</sub>O, and the concentration was measured spectrophotometrically at 260 nm. Using the following DNA template, 5'-*AGTAATACGACTCACTATAGGG*TACCCCTGATATGGCGCATTACGAC-3' (T7 promoter region highlighted in italics), the mis-match FIX aptamer was synthesized as described above using the same T7 forward primer and the reverse primer 5'-(T)<sub>24</sub>TACCCCTCCGTCGTAATGCGCCATAT-3' for a negative reaction.

### Interactive analyses of aptamer and FIX

Initially, the Au-sensing surface of SPR was modified using PEG-*b*-PAMA followed by SH-dT<sub>20</sub> and was duplexed with anti-factor aptamer extended with A<sub>24</sub>. Different concentrations of FIX (0.8 pM to 80 nM) were injected to determine the dissociation constant and sensitivity. On the FIX-immobilized surface, FIX antibody followed by GNP conjugated anti-mouse IgG (mouse-IgG-GNP) were passed. A four line Biacore system (Biacore 3000) was used for all the experiments. Among these, one flow channel was always used for the control experiment. Flow rates were as follows: PEG-*b*-PAMA (10 μL/min, 300 μl); SH-dT<sub>20</sub> and Aptamer-A<sub>24</sub> (2 μL/min, 20 μL); N6-PEG (10 μL/min, 300 μL); and FIX, FIX antibody, and mouse-IgG-GNP, (10 μL/min, 50 μL). Immobilized aptamers were regenerated using 10 mM NaOH (60 μL/min, 5 μl). All the measurements were carried out at 25°C.

To find the saturated concentration of each biomolecule for the strategy explained above, we titrated the optimal biomolecule concentration. First we injected different concentrations of PEG-*b*-PAMA (2 mg/mL to 50 mg/mL) on the Au surfaces. Then the different concentrations (1 μM to 5 μM) of SH-dT<sub>20</sub> were injected on the optimized PEG-*b*-PAMA immobilized surfaces. Similarly, we also titrated the aptamer concentration from 500 nM to 1000 nM on the optimized SH-dT<sub>20</sub>-modified surfaces. FIX antibody titration (25 nM to 200 nM) was carried out on the FIX (200 nM)-immobilized surfaces.

### Interactive analyses of antibody and FIX

Au surface modified with COOH by using 3-mercaptopropionic acid was used to immobilize the FIX antibody. The COOH-modified surface was activated by 100 mM *N*-hydroxysuccinimide (NHS) and *N*-ethyl-*N'*-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) to get an active ester surface. Then, 200 nM of the FIX antibody was passed directly on this surface. The remaining free COOH-surfaces were then

1  
2  
3 blocked using 10 mg/mL of N6-PEG or 1 M ethanolamine. Different concentrations of  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

FIX (30 nM to 240 nM) were injected on the FIX antibody-immobilized surfaces.

### **Dissociation constant of FIX-aptamer and FIX-antibody**

To find the dissociation (KD) value of FIX and aptamer, we injected different concentrations of FIX (15 nM to 120 nM) on the constant (500 nM) aptamer-immobilized surfaces. To check the FIX-antibody dissociation constant, we injected different concentrations of FIX (30 nM to 240 nM) on the constant FIX antibody (200 nM)-immobilized surfaces. KD value was calculated using the BIA Evaluation software by association and dissociation of FIX on aptamer- and antibody-immobilized surfaces. The rate of association was measured from the forward reaction, and the dissociation rate was measured from the reverse reaction. The equilibrium dissociation rate constant (KD) was calculated using the formula,  $kd/ka$  (KD, equilibrium dissociation constant;  $kd$ , dissociation rate; and  $ka$ , association rate).

### **Sandwich assay**

To detect FIX, here we performed two kinds of sandwich assay, which include aptamer-protein-antibody (200 nM antibody was passed on the aptamer-protein immobilized surfaces) and antibody-protein-aptamer (500 nM aptamer was passed on the antibody-protein immobilized surfaces). Different binding sites of the aptamer and antibody on FIX were confirmed by performing SPR and the gel-shift assay. For SPR, on the aptamer-FIX (120 nM)-immobilized surface, different concentrations (25 to 200 nM) of antibody were passed (10  $\mu$ L/min, 50  $\mu$ L). For the gel-shift assay, we used the native polyacrylamide gel electrophoresis (Native-PAGE). Before loading on the gel, the aptamer (0.3  $\mu$ g) was denatured at 90°C for 2 min and cooled to room temperature. Then, the pre-mix was made with different ratios of FIX (1:3, 1:6 and 1:9) in 10 mM HEPES-KOH (pH 7.4) buffer containing 150 mM NaCl and 2 mM CaCl<sub>2</sub>. The CaCl<sub>2</sub> was added after the denaturation step. Similarly, aptamer:FIX:antibody pre-mix was made

1  
2  
3 with different ratios (1:3:6, 1:3:12, and 1:3:24). After incubation at room temperature for  
4  
5 10 min, all the mixes were resolved by performing 10% native-PAGE. The control lane  
6  
7 was loaded with only the denatured aptamer. The gel was run at 150 V for 1 h and  
8  
9 stained with ethidium bromide. Then, the gel was destained with ddH<sub>2</sub>O, and the image  
10  
11 was photographed.

### 12 13 14 **Detection limit of FIX in the presence of albumin or human plasma**

15  
16  
17 To check the detection limit of FIX, we titrated FIX at different concentrations (from 0.8  
18  
19 pM to 80 nM) on the FIX aptamer (500 nM)-immobilized surfaces, followed by reaction  
20  
21 with constant FIX antibody (200 nM), and mouse-IgG-GNP (0.1 OD). Control  
22  
23 experiments were carried out with mis-match FIX aptamer. For selective binding, which  
24  
25 mimics a similar situation in the blood samples, experiments with mixed albumin was  
26  
27 carried out. Different concentrations of FIX (from 0.8 pM to 8000 pM) were mixed with  
28  
29 constant higher concentration of albumin (45 mg/mL) and passed on the FIX aptamer-  
30  
31 immobilized surface. Then, constant FIX antibody (200 nM) and mouse-IgG-GNP (0.1  
32  
33 OD) were injected. To detect the FIX in the human plasma, instead of FIX, we injected  
34  
35 different dilutions of human plasma (from 1:10 to 1:1280) by using half serial dilutions.  
36  
37 Similarly, spiking of FIX in 1:160 dilution of human blood plasma was performed  
38  
39 followed by analyses with SPR. All the other surface chemical modifications and  
40  
41 detection strategies were similar to those described previously.

### 42 43 **Results and discussion**

44  
45  
46 The objective of this work is to establish high-performance PEG hybridized sensing on  
47  
48 Au surfaces and we demonstrated here with one of the well-established SPR-based  
49  
50 sensors, Biacore. In order to prepare desirable sensor chip surface, poly(ethylene  
51  
52 glycol)-block-polyamines (PEG-*b*-polyamines), such as pentaethylenehexamine-  
53  
54 terminated PEG (N6-PEG) and PEG-*b*-poly[2-(N,N-dimethylamino)ethyl methacrylate]  
55  
56 (PEG-*b*-PAMA) were employed. As we reported previously<sup>41</sup>, PEG-*b*-PAMA with  
57  
58  
59  
60

1  
2  
3  
4 suitable polyamine chain length on gold sensor chip surface controls alignment of  
5 oligonucleotide. We would like to investigate this surface modification technique for  
6 aptamer surface. N6-PEG is anticipated for suppression of the bio-fouling as blocking  
7 agent. Human coagulating factor IX protein (FIX) was chosen as a model analyte to  
8 interact anti-FIX aptamer, because FIX has extremely low availability *in vivo* and  
9 important to detect defects in human blood coagulation system. With the  
10 complementation of aptamer and antibody, a sandwich pattern is designed with  
11 aptamer-FIX-antibody and higher sensitivity was attained with Gold nanoparticle (GNP)  
12 conjugated antibody.  
13  
14  
15  
16  
17  
18  
19  
20

### 21 **PEG-*b*-PAMA assisted the immobilization of aptamer on Au surface**

22  
23  
24

25 Prior to verifying the interaction of aptamer and factor IX (FIX), preliminary assessment  
26 was performed by immobilizing PEG-*b*-PAMA on Au surface at acidic (4.0), neutral  
27 (7.4), and alkaline (9.0) pH values. The responses obtained by SPR were similar at all  
28 the investigated pH conditions, which indicates the stability of PEG-*b*-PAMA under  
29 these conditions. Similar results under varied pH conditions was reported by Yoshimoto  
30 et al.<sup>41</sup> As the manufacturer recommended neutral pH (7.4) as ideal for the SPR system,  
31 further experiments were performed under this condition. At this pH, a higher response  
32 was obtained (1200 RU) with 6 mg/mL of PEG-*b*-PAMA-reconstructed surface, and the  
33 response increased further to only a few hundreds upon increasing the concentration to  
34 12, 25, and 50 mg/mL, suggesting that the saturation stage had been attained. Au  
35 surface can be stabilized through co-ordination of non-protonated amine and the  
36 adsorption of PEG-*b*-PAMA on the Au surface via multipoint coordination by the tertiary  
37 amino groups.<sup>41,46</sup> Once the PEG-*b*-PAMA is immobilized on the Au surface, it  
38 becomes very strong even under neutral conditions.<sup>41</sup> After attaching the PEG-*b*-PAMA  
39 on the Au surface, we analyzed the immobilization of thiolated-DNA oligo (SH-dT<sub>20</sub>) in  
40 order to make the duplex with the target aptamer (Supplementary Figure S2).  
41 Interestingly, we could observe a clear response (600 RU) at 1 μM concentration. The  
42 response increased further when the concentration of SH-dT<sub>20</sub> was increased to 2 μM  
43 (900); at the concentration of 3 μM, higher immobilization of SH-dT<sub>20</sub> on PEG-*b*-PAMA  
44 surface was detected (980 RU), which reached the saturation level. On the contrary,  
45 lower amount of SH-dT<sub>20</sub> was immobilized on bare Au surface even at this concentration  
46 (620 RU). PEG-*b*-PAMA assisted about 350 RU increment compared with the surface  
47 absence of PEG-*b*-PAMA (Figure 1). We have previously confirmed that the  
48 immobilization of sulfanyl-ended oligonucleotide increased significantly on the PEG-*b*-  
49 PAMA immobilized gold sensor surface<sup>41</sup>, which is ascribed to the electrostatic  
50 interaction of the negatively charged oligonucleotide and the positively charged gold  
51 surface. Because PAMA is polyamine homologues, it has positive charge. PEG-PAMA  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 modified surface possesses positive charge on the very periphery of the gold surface,  
4 attractive force between negatively charged SH-dT<sub>20</sub> and the surface might increase the  
5 modification efficiency regardless that PEG tethered chains tends to retard access of  
6 SH-dT<sub>20</sub> of the surface. This might be one of the reasons for increase in SH-dT<sub>20</sub>  
7 modifications as shown in Fig.1 Upon attaching aptamer-A<sub>24</sub>, the obtained values are  
8 ~700 and ~1000 RU for the sensing surface without and with PEG-*b*-PAMA,  
9 respectively, indicates the increment of ~300 RU (nearly equivalent to the value  
10 obtained from SH-dT<sub>20</sub> attachment) with the assistance of PEG-*b*-PAMA. Cationic  
11 charge of the PAMA segment on the periphery of the Au surface attracted anionic SH-  
12 dT<sub>20</sub> to result in increasing amount than that of bare Au surface, which possessed  
13 negative charge.<sup>46</sup> Previously, it was reported that PEG-*b*-PAMA-co-immobilized Au  
14 surface with SH-ssDNA inhibits the interaction of nucleobase of oligo and Au, and leads  
15 to upright confirmation of immobilized ssDNA. This confirmation further supports the  
16 proper duplex formation as described previously.<sup>47</sup> Moreover, PEG-*b*-PAMA-co-  
17 immobilized Au-nanoparticle with siRNA were shown to have higher interference  
18 efficiency have reported the role of PEG-*b*-PAMA on Au surface for the immobilization  
19 of SH-DNA and indicated that it would be stronger even under salt conditions.<sup>47,48</sup> Using  
20 this ideal situation, a stable anti-factor IX aptamer (2' fluoro-modified) extended with A<sub>24</sub>  
21 (20 bases for complementation and 4 bases for spacer) was immobilized. With the  
22 injection of FIX aptamer-A<sub>24</sub>, we could notice a proper duplex of the aptamer on the SH-  
23 dT<sub>20</sub> with nicely displayed sensogram to 900 RU, at the concentration of 500 nM. The  
24 aptamer-A<sub>24</sub> interaction with the SH-dT<sub>20</sub> detected higher response on the PEG-*b*-  
25 PAMA-modified surfaces compared to the surface free from PEG-*b*-PAMA (Figure 1).  
26 When the aptamer concentration was increased to 1 μM, the response was similar,  
27 indicating the saturation level of aptamer at 500 nM concentration (Supplementary  
28 Figure S3).

### 36 **Co-immobilization of PEG-*b*-PAMA and N6-PEG restricts biofouling on Au surface** 37 **for detection of FIX**

38  
39  
40  
41 After the construction of PEG-*b*-PAMA/ptmaer-A<sub>24</sub> surface, the efficiency of blocking  
42 treatment was analyzed using conventional BSA and our original N6-PEG, because the  
43 remaining Au-surface may disturb effective sensing. Mouse-IgG-GNP was employed for  
44 non-specific binding on these surfaces. When the PEG-*b*-PAMA/ptamer-A<sub>24</sub> surface  
45 was treated with 45 mg/mL of BSA, the signal (i.e. RU ~200) was definitely observed  
46 (Supplementary Figure S4), while no remarkable signal was observed by N6-PEG  
47 blocking, indicating a complete coverage by N6-PEG. N6-PEG (6 kDa) has 6 amino  
48 groups at one end of the PEG chain to interact with Au surface, and it has an  
49 electrostatically attractive force.<sup>15</sup> This polyamine interaction with Au-surface is stable for  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 a long-term than a common Au-S linkage, under varied physiological conditions.<sup>15,42</sup> To  
4 determine the stability and replacement of SH-dT<sub>20</sub> by N6-PEG, we performed two kinds  
5 of experiments. In one set-up after attachment of the aptamer-A<sub>24</sub> on SH-dT<sub>20</sub>, N6-PEG  
6 was passed and in the other case, the process was reversed (N6-PEG was passed on  
7 SH-dT<sub>20</sub> and then aptamer-A<sub>24</sub> was attached). In both the cases, we could find the same  
8 kind of responses, even with consequent injections of FIX at different concentrations  
9 (Supplementary Figure S5). With N6-PEG as a blocking agent, a similar response to  
10 FIX was observed, regardless of the order of the treatment (N6-PEG → aptamer-A<sub>24</sub>;  
11 aptamer-A<sub>24</sub> → N6-PEG), indicating the absence of the exchange of pre-immobilized  
12 SH-dT<sub>20</sub> by N6-PEG. When we passed the FIX on the PEG-*b*-PAMA- and N6-PEG-  
13 modified aptamer surfaces, a concomitant incremental enhancement in the responses  
14 was observed with increasing FIX concentrations (Figure 2a).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Dual polymers-assisted interaction: Determination of dissociation constant of** 27 **aptamer and FIX** 28 29 30

31 To access the dissociation constant of FIX and aptamer interaction in the presence of  
32 PEG-*b*-polyamines, we performed the experiments with different combinations of PEG-  
33 *b*-polyamines and compared the results with those for BSA-blocked Au surface. These  
34 combinations include, only BSA, only N6-PEG, only PEG-*b*-PAMA, PEG-*b*-PAMA with  
35 BSA, and PEG-*b*-PAMA with N6-PEG. Based on the responses obtained from lower  
36 concentrations (7.5 to 120 nM) of FIX, (Figure 2a) further evaluation was performed  
37 using the Biacore evaluation software, and were fitted with a 1:1 binding model (for the  
38 interaction between aptamer and FIX according to the equation A+B = AB). The lowest  
39 dissociation constant (KD) (highest sensitive) for aptamer and FIX interaction was 37 ±  
40 10 pM with the combinations of PEG-*b*-PAMA and N6-PEG. In other cases, for the  
41 same interaction, KDs were 685 ± 15 pM (only BSA), 450 ± 8 pM (only N6-PEG), 142 ±  
42 5 pM (only PEG-*b*-PAMA), and 81 ± 7 pM (PEG-*b*-PAMA and BSA) (Table 1). Among  
43 these, a dual PEG-*b*-polyamines (PEG-*b*-PAMA with N6-PEG) showed higher  
44 responses, which facilitated proper construction on the sensing surface and restricted  
45 fouling. Previously, it was proved that the KD of FIX and aptamer was 580 pM by filter  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 binding assay.<sup>44</sup> In this study, PEG-*b*-PAMA with N6-PEG polymers drastically reduced  
4 the background noise and improved the sensitivity and specificity, due to perfect  
5 blocking (by N6-PEG) and higher immobilization of aptamer in proper orientation (by  
6 PEG-*b*-PAMA). Another advantage of these kind of polymers is having lower molecular  
7 weights (~10 kDa) than other blocking agents such as BSA (66 kDa), casein (>20 kDa),  
8 and gelatin (>100 kDa). Higher molecular weight blocking causes interference with  
9 molecular-recognition site of the ligand and analyte.<sup>15</sup>  
10  
11  
12  
13  
14  
15  
16

### 17 **Determination of dissociation constant of antibody and FIX on the N6-PEG-** 18 **modified COOH surface** 19 20

21  
22 To compare the interactions of aptamer and FIX, we evaluated the KD of FIX antibody-  
23 FIX interaction on COOH-modified Au surface. We could observe the specific binding of  
24 FIX to the antibody on the Au surface in a dose-dependent manner, when ethanolamine  
25 was used as a blocking agent. However, we could also notice the non-specific binding  
26 of FIX even in the absence of antibody (Supplementary Figure S6a). Ethanolamine is  
27 considered as one of the common blocking agent for the COOH modified surfaces, but  
28 some of the active group on the COOH surface facilitates nonspecificity with FIX,  
29 because amine in the protein easily bind on the COOH surface. To avoid these  
30 nonspecific binding, the remaining COOH surfaces could be blocked by other blocking  
31 agents. Here, we used N6-PEG instead of ethanolamine, and it was found to completely  
32 quench the nonspecific binding of FIX by the strong binding of amine groups in the N6-  
33 PEG with COOH surfaces. N6-PEG not only suppresses the bio-fouling as shown in the  
34 figure, it also increases the specific responses in a concentration-dependent manner,  
35 compared with ethanolamine-blocked surfaces (Figure 2b and Supplementary Figure  
36 S6a & b). N6-PEG is not only suitable for Au surface, but is also very effective on  
37 COOH-modified surfaces. The KD for the specific interaction of FIX and antibody were  
38 determined as  $48 \pm 12$  nM. It is interesting to note that proper designing of aptamer or  
39 conventional antibody immobilization on the dual polymer-modified surface increased  
40 the sensing ability significantly.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Aptamer-FIX-antibody sandwich on PEGylated Au surface

Based on the findings of this study on FIX interactions with two different probes (aptamer and antibody), we designed the sandwich pattern on the aptamer-FIX-immobilized surface by interacting with anti-FIX antibody. In the past, aptamer-antigen-antibody sandwich assays have been considered to have a higher sensitivity.<sup>11</sup> In the sandwich assay, the key issue is the availability of two different binding sites on the target protein (FIX) for different probes (aptamer and antibody). To make sure that this issue is addressed, we performed confirmations with two kinds of experiments by analyzing SPR and gel-mobility shift. When we passed the antibody on the aptamer-FIX immobilized surface of SPR, we could see a concentration-dependent attachment of anti-FIX antibody (Figure 3a). This result confirmed the formation of a sandwich pattern of aptamer-FIX-antibody on the sensing surface. Similarly, we also evaluated the sandwich formation on the electrophoresis analysis by resolving different complexes (only aptamer, aptamer-FIX, and aptamer-FIX-antibody) on the native-PAGE. The resolved gel-pattern showed a clear shift with the aptamer-FIX complex and super-shift with the aptamer-FIX-antibody complexes in a dose-dependent manner (Figure 3b). Previously, by applying PEG/Antibody co-immobilized magnetic beads combined with a fluorescent system, a sandwich ELISA pattern was developed by our research team to detect alpha-fetoprotein.<sup>30</sup> In several instances, the aptamers are proposed as equal or better molecules than antibodies; however, both aptamer and antibody can complement each other in sandwich assays.<sup>11</sup> We also compared two different sandwich types, namely, aptamer-FIX-antibody and antibody-FIX-aptamer on the dual polymer (PEG-*b*-PAMA and N6-PEG)-immobilized Au surface. At FIX concentration of 120 nM, the response obtained was 350 RU in the case of aptamer-protein-antibody sandwich pattern. Whereas, under similar conditions, a response of 50 RU was obtained by antibody-FIX-aptamer strategy, suggesting a 7-fold lesser efficiency with the antibody-FIX-aptamer sandwich. This result indicates the higher affinity of aptamer than the conventional antibody for FIX, thus suggesting that ultimately aptamer captures higher

1  
2  
3 number of FIX molecules. Similarly, with the injection of different FIX concentrations (15  
4 to 120 nM), the aptamer-FIX-antibody strategy showed better responses, indicating the  
5 higher affinity of aptamer with FIX and suggesting that the higher molecular size of the  
6 antibody than that of the aptamer favors the suitability of aptamer-FIX-antibody strategy  
7 (Figure 4).  
8  
9  
10  
11

### 12 13 14 **Sensitive detection of FIX using mouse-IgG-GNP on PEG-*b*-PAMA- and N6-PEG- 15 co-immobilized Au surface** 16 17

18  
19 Based on the above sandwich pattern, we formulated a strategy with anti-mouse IgG-  
20 GNP for higher sensitivity by using the FIX antibody (Figure 5a). Based on the KD  
21 analyses aptamer has shown higher affinity (37 pM) than antibody (48 nM). To capture  
22 the higher number of antigen (FIX), we decided to immobilize aptamer on the sensing  
23 surface. To increase the sensitivity of detection, antibody was conjugated with GNP.  
24 The idea behind is increase in the molecular size increases the sensitivity, the sizes of  
25 both antibody and GNP are larger than aptamer. With this strategy, we performed the  
26 experiments on SPR with different combinations of blocking agents (only BSA, only N6-  
27 PEG, only PEG-*b*-PAMA, PEG-*b*-PAMA with BSA, and PEG-*b*-PAMA with N6-PEG)  
28 and injected FIX. When we injected 80 nM of FIX, a dual PEG-polymer (PEG-*b*-PAMA  
29 with N6-PEG) was shown to have higher responses (Figure 5b). We could observe 3-  
30 fold higher responses in the presence PEG-*b*-PAMA and N6-PEG unlike that observed  
31 for BSA used as a blocking agent, which might be due to the higher immobilization of  
32 SH-dT<sub>20</sub> and aptamer on the dual polymer-modified surface. Moreover, in the case of  
33 BSA blocking, higher non-specific attachment was noticed. With dual polymer surface  
34 construction, we determined the limit of detection of FIX as 800 fM with the response of  
35 about 200 RU. By increasing the FIX concentration, we could observe the clear  
36 incremental increase in the responses (Figure 6). These results suggest that PEG-*b*-  
37 polymers, have shown better performance rather than one of the common blocking  
38 agents, BSA. In addition, co-immobilization of dual polymers is good for bio-sensing,  
39 compared to single-polymer application.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 The biological importance of FIX was demonstrated in Hemophilia B (Christmas  
6 disease), when the FIX concentration in plasma reaches abnormal levels compared to  
7 the normal level of around 5  $\mu\text{g/mL}$  (87 nM). The plasma sample contain albumin as the  
8 major protein with other clotting factors in addition to FIX. If we can detect FIX  
9 selectively among these active major proteins, it is anticipated that we will be able to  
10 precisely determine the level of FIX. Human blood serum contain albumin at the level of  
11  $\sim 45 \text{ mg/mL}$  ( $\sim 55\%$ ).<sup>24</sup> To check the selective binding of FIX protein in the presence of  
12 albumin, we performed the experiment using FIX mixed with a high concentration of  
13 albumin (45 mg/mL). With this enhanced albumin concentration, we titrated the FIX until  
14 80 nM which is close to the real concentration in the human plasma and we could detect  
15 FIX at 80 pM (Figure 6). Higher sensitivity was attained in the mixed sample using the  
16 sandwich pattern with anti-mouse IgG-GNP due to PEG-*b*-PAMA- and N6-PEG-  
17 immobilized Au surface. Hence, this can be used as the common strategy for any  
18 aptamer-protein interactions. Further, SH-dT<sub>20</sub> and aptamer-A<sub>24</sub> duplex could be  
19 regenerated by injecting 10 mM NaOH on the sensing surface (Supplementary figure  
20 S7a & b). We detected FIX with high concentrations of albumin, which mimics  
21 physiological condition, suggesting that the present strategy is suitable for detecting FIX  
22 deficiency in human blood samples.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Detection of FIX in human plasma on co-immobilized PEG-*b*-PAMA and N6-** 40 **PEGmodified Au surface** 41

42  
43  
44 Human blood plasma in addition to albumin also contains other clotting factors,  
45 including FIX involved in the human blood-clotting system and participates in the  
46 cleavage in the intrinsic and extrinsic clotting pathways.<sup>45</sup> To further confirm the present  
47 results, we directly used human plasma and evaluated the existing FIX using the  
48 designed strategy with GNP. We evaluated the serially diluted human blood plasma  
49 from 1:10 to 1:1280 dilution, which is equivalent to the dilutions from 8 nM to 0.062 nM  
50 of FIX. Upon injection, we could observe the clear changes in the sensogram with the  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 dilution of 1:160, which is equivalent to 500 pM of FIX, and at this concentration, the  
4 change in the sensorgram was 250 RU (Supplementary Figure S8). To rule out non-  
5 specific binding of serum proteins, we evaluated mismatching aptamer sequence, and  
6 no binding was noticed both by SPR and gel-shift assay analyses (Supplementary  
7 Figure S9). Similarly, the pre-mix of specific aptamer without poly-A tail (cannot make a  
8 duplex with SH-dT<sub>20</sub>) and FIX caused reduction in the binding, with increasing  
9 concentration of the pre-mixed aptamer (Supplementary Figure S10a & b). To confirm  
10 the genuine interaction of aptamer and FIX in plasma, we mixed the pure FIX at  
11 different concentrations to the plasma upto 1:160 dilution, where we could not detect  
12 FIX. Upon mixing the FIX, we would observe the changes in the sensorgram in a  
13 concentration-dependent manner (Figure 7a&b). The results obtained with human  
14 plasma using the designed strategy here indicates its suitability to analyse the  
15 deficiency of FIX in human blood samples.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **Conclusions**


29  
30  
31 In this study, using dual PEG-block polymers (PEG-*b*-PAMA and N6-PEG)-co-  
32 immobilized Au-sensing surface of SPR, a detection strategy was formulated for the  
33 detection of FIX with the assistance of FIX-aptamer and FIX-antibody in a sandwich  
34 pattern. The detection was performed with anti-mouse IgG-GNP. PEG-*b*-PAMA-treated  
35 Au surface promoted the proper orientation of thiolated DNA oligos on the Au surface  
36 with higher number of molecules. Co-immobilization of N6-PEG with PEG-*b*-PAMA  
37 completely abolished the bio-fouling, whereas BSA showed higher non-specificity. With  
38 dual polymer construction, the limit of detection was enhanced to 800 fM. Further, the  
39 selective FIX detection was shown with albumin containing sample. In addition, the  
40 utility of the present polymer-assisted detection strategy was demonstrated by the  
41 detection of FIX in human blood plasma, indicating its application in the detection of  
42 clinically relevant samples.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **Notes and references**


- 1
- 2
- 3
- 4
- 5 1. Y. Li, H.J. Schluesener and S. Xu, *Gold Bulletin* 2010, **43**, 29.
- 6
- 7 2. X.J. Guo, *Biophotonics* 2012, **5**, 483.
- 8
- 9 3. J. Homola, S.S. Yee and G. Gauglitz, *Sens. Actuat.* 1999, **54**, 3.
- 10
- 11 4. M. Jing and M.T. Bowser, *Anal. Chim. Acta* 2011, **686**, 9.
- 12
- 13 5. K. Catt and H.D. Niall, *Nature* 1967, **213**, 825.
- 14
- 15 6. E. Engvall, and P. Permann, *Immunochemistry* 1971, **8**, 871.
- 16
- 17 7. B. Hock, *Anal. Chim. Acta* 1997, **347**, 177.
- 18
- 19 8. C. Tuerk and L. Gold, *Science* 1990, **249**, 505.
- 20
- 21 9. A.D. Ellington and J.W. Szostak, *Nature* 1990, **346**, 818.
- 22
- 23 10. D.L. Robertson and G.F. Joyce, *Nature* 1990, **344**, 467.
- 24
- 25 11. S. Kim, J. Lee, S.J. Lee and H.J. Lee, *Talanta* 2010, **81**, 1755.
- 26
- 27 12. S. Kanno, Y. Yanagida, T. Haruyama, E. Kobatake and Aizawa, M. *J. Biotechnol.* 2000, **76**,  
28 207.
- 29
- 30 13. B. Lu, M.R. Smyth and R. O'Kennedy, *Analyst* 1996, **121**, 29R.
- 31
- 32 14. S. Kumar, R. Ch, D. Rath and S. Panda, *Mate. Sci. Eng.* 2011, **31**, 370.
- 33
- 34 15. Y. Nagasaki, *Poly. J.* 2011, **43**, 949.
- 35
- 36 16. M. Oishi, S. Sasaki, Y. Nagasaki and K. Kataoka, *Biomacromolecules* 2003, **4**,  
37 1426.
- 38
- 39 17. M. Oishi, Y. Nagasaki, K. Itaka, N. Nishiyama and K. Kataoka, *J. Am. Chem. Soc.*  
40 2005, **127**, 1624.
- 41
- 42 18. M. Yuan, K. Yoshimoto and Y. Nagasaki, *Anal. Chem.* 2009, **81**, 1549.
- 43
- 44 19. V.S. Trubetskoy, *Adv. Drug Deliv. Rev.* 1999, **37**, 81.
- 45
- 46 20. H. Otsuka, Y. Nagasaki and K. Kataoka, *Adv. Drug Deliv. Rev.* 2003, **55**, 403.
- 47
- 48 21. G. L. Kenausis, J. Vörös, D. L. Elbert, N. P. Huang, R. Hofer, L. Ruiz-Taylor, M.  
49 Textor, J. A. Hubbell and N. D. Spencer, *J. Phys. Chem. B* 2000, **104**, 3298.
- 50
- 51 22. R. Langer and J. P. Vacanti, *Science* 1993, **260**, 920.
- 52
- 53 23. M E. Baker, *J. Endocrinol.* 2002, **175**, 121.
- 54
- 55 24. F.E.J.V.K. Bailey, *Marcel Dekker Inc., New York*, 1990.
- 56
- 57 25. M. Malmsten, K. Emoto and J.M. Van Alstine, *J. Colloid Interface Sci.* 1998, **202**,  
58 507.
- 59
- 60

- 1  
2  
3 26. H. Otsuka, Y. Nagasaki and K. Kataoka, *Langmuir* 2004, **20**, 11285.  
4  
5 27. T. Satomi, Y. Nagasaki, H. Kobayashi, H. Otsuka and Kataoka, K. *Langmuir* 2007,  
6  
7 **23**, 6698.  
8  
9 28. K. Uchida, H. Otsuka, M. Kaneko, K. Kataoka and Y. Nagasaki, *Anal. Chem.* 2005,  
10  
11 **77**, 1075.  
12 29. Y. Nagasaki, H. Kobayashi, Y. Katsuyama, T. Jomura and T. Sakura, *J. Colloid*  
13  
14 *Interface Sci.* 2007, **309**, 524.  
15  
16 30. M. Kamimura, D. Miyamoto, Y. Saito, K. Soga and Y. Nagasaki, *Langmuir* 2008,  
17  
18 **24**, 8864.  
19  
20 31. K. Yoshimoto, M. Nishio, H. Sugawara and Y. Nagasaki, *J. Am. Chem. Soc.* 2010,  
21  
22 **132**, 7982.  
23  
24 32. Z. Lim, J. Li, C. Ng, L.L. Yung and B. Bay, *Acta Pharmacol. Sinica* 2011, **32**, 983.  
25  
26 33. A.B. Iliuk, L. Hu and W.A. Tao, *Anal. Chem.* 2011, **83**, 4440.  
27  
28 34. V.K. Upadhyayula, *Anal. Chim. Acta.* 2012, **715**, 1.  
29  
30 35. B.S. Guirgis, C. Sá E Cunha, I. Gomes, M. Cavadas, I. Silva, G. Doria, G.L. Blatch,  
31  
32 P.V. Baptista, E. Pereria, H.M. Azzazy, M.M. Mota, M. Prudencio, and R. Franco,  
33  
34 *Anal. Bioanal. Chem.* 2012, **402**, 1019.  
35  
36 36. L.M. Zanolli, R. D'Agata and G. Spoto, *Anal. Bioanal. Chem.* 2012, **402**, 1759.  
37  
38 37. D. Miyamoto, M. Oishi, K. Kojima, K. Yoshimoto and Y. Nagasaki, *Langmuir* 2008,  
39  
40 **24**, 5010.  
41  
42 38. K.V. Gobi, H. Iwasaka and N. Miura. *Biosens. Bioelectron.* 2007, **22**, 1382.  
43  
44 39. K. V. Gobi, K. Matsumoto, K. Toko and N. Miura. *Sens. & Instrumen. Food Qual.*  
45  
46 2008, **2**, 225.  
47  
48 40. K. Yoshimoto, M. Nozawa, S. Matsumoto, T. Echigo, S. Nemoto, T. Hatta and Y.  
49  
50 Nagasaki, *Langmuir* 2009, **25**, 12243.  
51  
52 41. K. Yoshimoto, S. Matsumoto, R. Asakawa, K. Uchida, T. Ishii and Y. Nagasaki,  
53  
54 *Chem. Lett.* 2007, **36**, 1444.  
55  
56 42. T. Lakshmipriya, M. Fujimaki, S.C.B. Gopinath, K. Awazu, Y. Horiguchi and Y.  
57  
58 Nagasaki, *Analyst* 2013, **138**, 2863  
59  
60 43. Y. Horiguchi, S. Miyachi and Y. Nagasaki, *Langmuir* 2013, **29**, 7369.


- 1  
2  
3  
4 44. C.P. Rusconi, D. Scardino, J. Layzer, G.A. Pitoc, T.L. Ortel, D. Monroe, B.A.  
5 Sullenger, *Nature* 2002, **419**, 90.  
6  
7 45. S.C.B. Gopinath, Y. Shikamoto, H. Mizuno and P.K.R. Kumar, *Thromb.*  
8 *Haemostasis* 2006, **95**, 767.  
9  
10 46. Y. Nagasaki, *Chem. Lett.* 2008, **37**, 564.  
11  
12 47. M. Oishi, K. Kataoka and Y. Nagasaki, *Bioconjugate Chem.* 2006, **17**, 677.  
13  
14 48. H. Furusho, K. Kitano, S. Hamaguchi and Y. Nagasaki, *Chem. Mater.* 2009, **21**,  
15 3526.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 1.** Evaluation of immobilization of SH-dT<sub>20</sub> and aptamer-A<sub>24</sub>-duplex formation on Au surface. Difference in the immobilization in the presence and absence of PEG-*b*-PAMA (6 mg/mL) was tested. About 3  $\mu$ M of SH-dT<sub>20</sub> was injected then duplexed with 500 nM aptamer-A<sub>24</sub>. With SH-dT<sub>20</sub> the obtained values are 620 and 980 RU for the sensing surface without and with PEG-*b*-PAMA, respectively. Upon attaching aptamer-A<sub>24</sub>, the obtained values are ~700 and ~1000 RU for the sensing surface without and with PEG-*b*-PAMA, respectively. The schematic illustrates the strategies.




**Figure 2.** Determination of dissociation constant. (a) FIX-aptamer interaction. FIX at different concentrations (7.5 to 120 nM) was passed on the FIX aptamer-immobilized surface. (b) FIX-antibody interaction. FIX at different concentrations (15 to 240 nM) was passed on the FIX antibody-immobilized surface. The samples were injected at the flow rate of 10  $\mu$ l/min. All the experiments were performed using 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl and 2 mM CaCl<sub>2</sub>.




**Figure 3.** Analyses of sandwich formation with aptamer-FIX-antibody. (a) SPR analyses of the complex formation of aptamer-FIX-antibody on surface modified by PEG-polymers. After immobilization of the aptamer (500 nM) and blocking with N6-PEG on Au surface, FIX (200 nM) was attached. On the FIX-immobilized surface, different concentrations of FIX-antibody was passed. The inset in the figure is for a schematic representation of this complex. Samples were injected at the flow rate of 10  $\mu\text{L}/\text{min}$ . (b) Native-polyacrylamide gel electrophoresis analysis of the complex of aptamer-FIX-antibody. Shift and super-shifts are shown with aptamer-FIX and aptamer-FIX-antibody complexes. All the experiments were performed with 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl and 2 mM  $\text{CaCl}_2$ .




**Figure 4.** Analyses of sandwich patterns on PEGylated surface. Aptamer-FIX-antibody and antibody-FIX-aptamer sandwich were compared. After immobilization of aptamer (500 nM) or antibody (200 nM) and blocking with N6-PEG on Au surface, FIX (15–120 nM) was attached. On the FIX-immobilized surface, FIX-antibody or aptamer was passed. Figure inset represents the schematic of this complex. Samples were injected at the flow rate of 10  $\mu$ L/min.



**Figure 5.** a) Schematic of chemical surface modifications on the Au surface of the SPR-sensing plate for aptamer and FIX interactions. (b) Detection of FIX on Au surface with different blocking agents. After immobilization of the aptamer (500 nM) and blocking with different agents on Au surface, FIX (80 nM) was attached. On the FIX-immobilized surface, 200 nM of FIX-antibody was passed. Detection was performed using anti-mouse IgG-GNP. The samples were injected at the flow rate of 10  $\mu$ L/min.



**Figure 6.** Detection limit of FIX in the presence or absence of albumin. FIX in the range of 0.008 to 80,000 pM were tested. All the experiments were performed with 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl and 2 mM CaCl<sub>2</sub>. Detection limits are indicated by arrows. Samples were injected at the flow rate of 10  $\mu$ l/min.




**Figure 7.** Spiking of FIX in human blood plasma. (a) SPR analyses. Different concentrations (0.08 to 80 pM) of FIX were spiked in 1:160-diluted human blood plasma. The samples were injected at the flow rate of 10  $\mu\text{L}/\text{min}$ . All the experiments were performed with 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl and 2 mM  $\text{CaCl}_2$ . (b) Graphical representation of the results obtained from SPR analyses.

**Table 1.** Kinetic parameters for the interaction of aptamer and FIX in the presence of different combinations of PEG-b-polymers

<b>Blocking agent</b>	<b>Association constant <math>K_a</math> (<math>M^{-1}s^{-1}</math>)</b>	<b>Dissociation constant <math>K_d</math> (<math>s^{-1}</math>)</b>	<b>Equilibrium constant <math>KD</math> (M)</b>
BSA	$4.16 \times 10^4$	$2.85 \times 10^{-5}$	$6.85 \pm 1.5 \times 10^{-10}$
N6-PEG	$2.8 \times 10^4$	$1.26 \times 10^{-5}$	$4.5 \pm 0.8 \times 10^{-10}$
PEG-b-PAMA	$2.44 \times 10^4$	$3.46 \times 10^{-6}$	$1.42 \pm 0.5 \times 10^{-10}$
PEG-b-PAMA & BSA	$3.86 \times 10^4$	$3.13 \times 10^{-6}$	$8.1 \pm 0.7 \times 10^{-11}$
PEG-b-PAMA & N6-PEG	$3.4 \times 10^4$	$1.26 \times 10^{-6}$	$3.7 \pm 1.0 \times 10^{-11}$

Lakshmipriya et al. (TOC only)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60